Based on the immuno-histochemical expression of the three markers, the proportion of breast cancer subtypes seen in this study were: Lumina A tumors 18 (34.6%), Lumina B tumors 9 (17.3%), HER-2 Enriched tumors 5 (9.6%) and Triple negative tumors 20 (38.4%). Here, ERBB2 is linked to breast carcinoma.